Your browser doesn't support javascript.
Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis.
Mehta, Meenu; Prasher, Parteek; Sharma, Mousmee; Shastri, Madhur D; Khurana, Navneet; Vyas, Manish; Dureja, Harish; Gupta, Gaurav; Anand, Krishnan; Satija, Saurabh; Chellappan, Dinesh Kumar; Dua, Kamal.
  • Mehta M; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India.
  • Prasher P; Department of Chemistry, University of Petroleum & Energy Studies, Dehradun 248007, India.
  • Sharma M; Department of Chemistry, Uttaranchal University, Dehradun 248007, India.
  • Shastri MD; School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, TAS 7250, Australia.
  • Khurana N; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India.
  • Vyas M; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India.
  • Dureja H; Faculty of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, India.
  • Gupta G; School of Pharmacy, Suresh Gyan Vihar University, Jagatpura 302017, Mahal Road, Jaipur, India.
  • Anand K; Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences and National Health Laboratory Service, University of the Free State, Bloemfontein, South Africa.
  • Satija S; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India.
  • Chellappan DK; Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000 Kuala Lumpur, Malaysia.
  • Dua K; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, The University of Newcastle (UoN), Callaghan, NSW 23
Med Hypotheses ; 144: 110254, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-753089
ABSTRACT
The highly contagious coronavirus, which had already affected more than 2 million people in 210 countries, triggered a colossal economic crisis consequently resulting from measures adopted by various goverments to limit transmission. This has placed the lives of many people infected worldwide at great risk. Currently there are no established or validated treatments for COVID-19, that is approved worldwide. Nanocarriers may offer a wide range of applications that could be developed into risk-free approaches for successful therapeutic strategies that may lead to immunisation against the severe acute respiratory syndrome coronavirus 2 (SARS­CoV­2) which is the primary causative organism that had led to the current COVID-19 pandemic. We address existing as well as emerging therapeutic and prophylactic approaches that may enable us to effectively combat this pandemic, and also may help to identify the key areas where nano-scientists can step in.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Delivery Systems / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Traditional medicine Limits: Humans Language: English Journal: Med Hypotheses Year: 2020 Document Type: Article Affiliation country: J.mehy.2020.110254

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Delivery Systems / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Traditional medicine Limits: Humans Language: English Journal: Med Hypotheses Year: 2020 Document Type: Article Affiliation country: J.mehy.2020.110254